1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 10,42 € (+195,18 %). La mediana es de 10,42 € (+195,18 %).
| Comprar |
0 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
Zivo Bioscience switches trading to OTCID platform
Zivo Bioscience has transferred its common shares to the OTCID marketplace and has been traded there since Monday. The company, with a market capitalization of $15.21 million, recorded revenue growth of 165% over the past twelve months but remains unprofitable. The stock has fallen 78% year over year and is currently trading at $3.80; existing shareholders keep their holdings. Zivo will continue to provide corporate and financial information via the OTC Markets disclosure page to ensure transparency and market presence. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 0 | 100,00 % |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | -449,04 mil | 67,73 % |
| EBITDA | -445,98 mil | 67,81 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 13,84 M € |
Número de acciones | 3,89 M |
Máximo/mínimo de 52 semanas | 15,19 € - 0,96 € |
| Dividendos | No |
Beta | 0,11 |
Ratio P/E | -2,93 |
Ratio PEG | -0,05 |
Ratio P/B | -5,03 |
Ratio P/S | 242,94 |
Perfil de la empresa
| Nombre | Zivo Bioscience |
| CEO | John Bernard Payne |
| Empleados | 7 |
